Hypertrophied myocardium is refractory to sevoflurane-induced protection with alteration of reperfusion injury salvage kinase/glycogen synthase kinase 3β signals

Shock

Volumn 40, Issue 3, 2013, Pages 217-221

  Ma, Lei Lei ^a   Zhang, Fei Jiang ^a   Kong, Fei Juan ^b   Qian, Ling Bo ^a   Ma, Hong ^a   Wang, Jian An ^a   Yan, Min ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

cardiac hypertrophy; cardioprotection; postconditioning; Sevoflurane, GSK3"

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE; PROTEIN KINASE B; REPERFUSION INJURY SALVAGE KINASE; SEVOFLURANE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; HEART HEMODYNAMICS; HEART INFARCTION SIZE; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; ISCHEMIC POSTCONDITIONING; ISOLATED HEART; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; REPERFUSION INJURY; SHAM PROCEDURE; SIGNAL TRANSDUCTION;

ANIMALS; GLYCOGEN SYNTHASE KINASE 3; MALE; METHYL ETHERS; MYOCARDIUM; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; REPERFUSION INJURY; SIGNAL TRANSDUCTION;

EID: 84883278156     PISSN: 10732322     EISSN: 15400514     Source Type: Journal    
DOI: 10.1097/SHK.0b013e3182a0674b     Document Type: Article

References (18)

1. Ferdinandy P, Schulz R, Baxter GF: Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev 59(4):418Y458, 2007.
2. Grall S, Prunier-Mirebeau D, Tamareille S, Mateus V, Lamon D, Furber A, Prunier F: Endoplasmic reticulum stress pathway involvement in local and remote myocardial ischemic conditioning. Shock 39(5):433Y439, 2013.
3. Pagel PS: Postconditioning by volatile anesthetics: salvaging ischemic myocardium at reperfusion by activation of prosurvival signaling. J Cardiothorac Vasc Anesth 22(5):753Y765, 2008.
4. Lecour S: Activation of the protective survivor activating factor enhancement (SAFE) pathway against reperfusion injury: does it go beyond the RISK pathway? J Mol Cell Cardiol 47(1):32Y40, 2009.
5. Juhaszova M, Zorov DB, Yaniv Y, Nuss HB, Wang S, Sollott SJ: Role of glycogen synthase kinase-3beta in cardioprotection. Circ Res 104(11): 1240Y1252, 2009.
6. Wu QL, Shen T, Shao LL, Ma H, Wang JK: Ischemic postconditioning mediates cardioprotection via PI3K/GSK-3"/"-catenin signaling pathway in ischemic rat myocardium. Shock 38(2):165Y169, 2012.
7. Siddall HK, Warrell CE, Yellon DM, Mocanu MM: Ischemia-reperfusion injury and cardioprotection: investigating PTEN, the phosphatase that negatively regulates PI3K, using a congenital model of PTEN haploinsufficiency. Basic Res Cardiol 103(6):560Y568, 2008.
8. Mocanu MM, Yellon DM: PTEN, the Achilles? heel of myocardial ischaemia/reperfusion injury? Br J Pharmacol 150(7):833Y838, 2007.
9. Keyes KT, Xu J, Long B, Zhang C, Hu Z, Ye Y: Pharmacological inhibition of PTEN limits myocardial infarct size and improves left ventricular function postinfarction. Am J Physiol 298(4):H1198YH1208, 2010.
10. Vakili BA, Okin PM, Devereux RB: Prognostic implications of left ventricular hypertrophy. Am Heart J 141(3):334Y341, 2001.
11. Wagner C, Ebner B, Tillack D, Strasser RH, Weinbrenner C: Cardioprotection by ischemic postconditioning is abrogated in hypertrophied myocardium of spontaneously hypertensive rats. J Cardiovasc Pharmacol 61(1):35Y41, 2013.
12. Zheng Z, Yang M, Zhang F, Yu J, Wang J, Ma L, Zhong Y, Qian L, Chen G, Yu L, et al.: Gender-related difference of sevoflurane postconditioning in isolated rat hearts: focus on phosphatidylinositol-3-kinase/Akt signaling. J Surg Res 170(1):e3Ye9, 2011.
13. Inserte J, Barba I, Poncelas-Nozal M, Hernando V, Agulló L, Ruiz-Meana M, Garcia-Dorado D: cGMP/PKG pathway mediates myocardial postconditioning protection in rat hearts by delaying normalization of intracellular acidosis during reperfusion. J Mol Cell Cardiol 50(5):903Y909, 2011.
14. Perlini S, Palladini G, Ferrero I, Tozz R, Fallarin S, Facoetti A, Nano R, Clari F, Busca G, Fogari R, Ferrari AU: Sympathectomy or doxazosin, but not propranolol, blunt myocardial interstitial fibrosis in pressure-overload hypertrophy. Hypertension 46(5):1213Y1218, 2005.
15. Bell RM, Mocanu MM, Yellon DM: Retrograde heart perfusion: the Langendorff technique of isolated heart perfusion. J Mol Cell Cardiol 50(6):940Y950, 2011.
16. Zhang FJ, Ma LL, Wang WN, Qian LB, Yang MJ, Yu J, Chen G, Yu LN, Yan M: Hypercholesterolemia abrogates sevoflurane-induced delayed preconditioning against myocardial infarct in rats by alteration of nitric oxide synthase signaling. Shock 37(5):485Y491, 2012.
17. Yano T, Miki T, Tanno M, Kuno A, Itoh T, Takada A, Sato T, Kouzu H, Shimamoto K, Miura T: Hypertensive hypertrophied myocardium is vulnerable to infarction and refractory to erythropoietin-induced protection. Hypertension 57(1):110Y115, 2011.
18. Dai W, Simkhovich BZ, Kloner RA: Ischemic preconditioning maintains cardioprotection in aging normotensive and spontaneously hypertensive rats. Exp Gerontol 44(5):344Y349, 2009.